Sanofi India Limited has informed the Exchange regarding Outcome of Board Meeting held on July 16, 2025.
SANOFI · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 0.7 pts more than Nifty Microcap 250 and 0.7 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Sanofi India's board approved three key items on July 16, 2025. First, current CFO Mr. Rachid Ayari will additionally serve as Interim Managing Director for 6 months from July 21, 2025 to January 20, 2026, or until a permanent MD is appointed, filling the vacancy left by Mr. Rodolfo Hrosz who ceased as MD on April 30, 2025. Second, Mr. Aniket Raje was appointed as Head of Regulatory Affairs effective August 1, 2025; he has 21+ years of pharma experience and was previously at Sanofi Healthcare India. Third, the board approved an exclusive 5-year distribution and promotion agreement with Emcure Pharmaceuticals for Sanofi's oral anti-diabetic brands Amaryl® and Cetapin® in India. Sanofi will continue to own and manufacture these products, while Emcure will handle distribution and healthcare professional engagement across India. No employees will transfer from Sanofi to Emcure under this arrangement.
The dual CFO-Interim MD role provides leadership continuity during the search for a permanent head. The Emcure partnership leverages Emcure's wide Indian distribution network to expand reach of Sanofi's established diabetes brands to over 100 million type-2 diabetes patients in India, potentially boosting sales, though it signals a strategic shift toward outsourced distribution for this segment.